In an analysis of patients with hepatocellular carcinoma treated with MTL-CEBPA and sorafenib, we observed a trend of CEBPA mRNA upregulation associated with outcome, though we did not detect an association between CEBPA mRNA upregulation with outcome in TIMEPOINT. This evidence concerns the gene CEBPA and hepatocellular carcinoma.